Should I buy or sell Panbela Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Panbela Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PBLA shares. View PBLA analyst ratings or view top-rated stocks .

What is Panbela Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price objectives for Panbela Therapeutics' stock. Their PBLA share price targets range from $500.00 to $500.00. On average, they predict the company's share price to reach $500.00 in the next twelve months. This suggests a possible upside of 118,947.6% from the stock's current price. View analysts price targets for PBLA or view top-rated stocks among Wall Street analysts .

How have PBLA shares performed in 2024?

Panbela Therapeutics' stock was trading at $18.30 on January 1st, 2024. Since then, PBLA stock has decreased by 97.7% and is now trading at $0.42. View the best growth stocks for 2024 here .

When is Panbela Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PBLA earnings forecast .

How were Panbela Therapeutics' earnings last quarter?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($159.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($94.20) by $64.80. During the same quarter last year, the business earned ($36,276.20) earnings per share.

When did Panbela Therapeutics' stock split?

Panbela Therapeutics's stock reverse split on Thursday, January 18th 2024. The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Panbela Therapeutics?

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PBLA

Panbela Therapeutics (PBLA) Stock Price, News & Analysis

→ New York goes dark, then America. (From Porter & Company) (Ad)

Free PBLA Stock Alerts

$0.42

-0.07 (-14.29%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.40
▼
$0.49
50-Day Range: $0.42
▼
$1.36
52-Week Range: $0.40
▼
$477.00

Volume: 263,022 shs
Average Volume: 602,327 shs
Market Capitalization: $1.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $500.00

Get Panbela Therapeutics alerts:

Panbela Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 118,947.6% Upside
$500.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.25) to ($3.74) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.01 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Panbela Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Panbela Therapeutics has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PBLA.

0.0

Dividend Strength

Dividend Yield
Panbela Therapeutics does not currently pay a dividend.
Dividend Growth
Panbela Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PBLA.

1.8

News and Social Media Coverage

News Sentiment
Panbela Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Panbela Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 12 people have searched for PBLA on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Panbela Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Panbela Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.01% of the stock of Panbela Therapeutics is held by insiders.
Percentage Held by Institutions
Only 4.37% of the stock of Panbela Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Panbela Therapeutics are expected to grow in the coming year, from ($5.25) to ($3.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Panbela Therapeutics Stock (NASDAQ:PBLA)

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

PBLA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PBLA Stock News Headlines

April 18, 2024 | marketwatch.com

Panbela Applies to List on CBOE

April 18, 2024 | globenewswire.com

Panbela Announces Poster Presentation at American Association for Cancer Research:

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | finanznachrichten.de

Panbela Therapeutics, Inc.: Panbela Announces Transfer to OTCQB Market

April 16, 2024 | finance.yahoo.com

Panbela Announces Transfer to OTCQB Market

March 28, 2024 | benzinga.com

Recap: Panbela Therapeutics Q4 Earnings

March 28, 2024 | seekingalpha.com

Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript

March 27, 2024 | msn.com

Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call Transcript

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 27, 2024 | finanznachrichten.de

Panbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

March 26, 2024 | globenewswire.com

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

March 26, 2024 | benzinga.com

Earnings Preview: Panbela Therapeutics

March 22, 2024 | seekingalpha.com

PBLA Panbela Therapeutics, Inc.

March 12, 2024 | globenewswire.com

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

February 23, 2024 | msn.com

Top 4 Health Care Stocks That Are Preparing To Pump This Month

February 23, 2024 | benzinga.com

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

February 15, 2024 | finance.yahoo.com

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

February 15, 2024 | globenewswire.com

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

February 1, 2024 | finance.yahoo.com

Panbela Announces Closing of Approximately $9.0 Million Public Offering

January 31, 2024 | investing.com

Panbela Therapeutics Inc (PBLA)

January 30, 2024 | finanznachrichten.de

Panbela Therapeutics, Inc.: Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

January 30, 2024 | benzinga.com

What's Going On With Panbela Therapeutics Stock Today?

January 30, 2024 | finance.yahoo.com

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

January 29, 2024 | msn.com

Panbela Therapeutics, Processa Pharmaceuticals among healthcare movers

January 29, 2024 | markets.businessinsider.com

Panbela Therapeutics Prices $9 Mln Share Offering

January 29, 2024 | investorplace.com

Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?

January 29, 2024 | marketwatch.com

Panbela Therapeutics Shares Slide Premarket After Public Offering

See More Headlines

Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/10/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PBLA
CUSIP: N/A
CIK: 1029125
Web: www.panbela.com
Phone: (952) 479-1196
Fax: N/A
Employees: 6
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $500.00
High Stock Price Target: $500.00
Low Stock Price Target: $500.00
Potential Upside/Downside: +118,947.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($669.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-25,260,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -70,194.55%
Return on Assets: -172.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.25
Quick Ratio: 0.25

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($18.37) per share
Price / Book: -0.02

Miscellaneous

Outstanding Shares: 3,480,000
Free Float: 3,481,000
Market Cap: $1.46 million
Optionable: Not Optionable
Beta: 1.48

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Jennifer K. Simpson CRNP (Age 56)
M.S.N., Ph.D., CEO, President & Director
Comp: $527k
Ms. Susan Horvath (Age 65)
VP of Finance, CFO, Secretary & Treasurer
Comp: $333k
Ms. Tammy Groene
Vice President of Operations
Dr. Elizabeth Bruckheimer Ph.D.
VP & Chief Scientific Officer

Key Competitors

View All Competitors

Insiders

Goldman Sachs Group Inc
Sold 3,643 shares
Total: $51,730.60 ($14.20/share)

View All Insider Transactions

PBLA Stock Analysis - Frequently Asked Questions

Should I buy or sell Panbela Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Panbela Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PBLA shares.
View PBLA analyst ratings or view top-rated stocks.
What is Panbela Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued twelve-month price objectives for Panbela Therapeutics' stock. Their PBLA share price targets range from $500.00 to $500.00. On average, they predict the company's share price to reach $500.00 in the next twelve months. This suggests a possible upside of 118,947.6% from the stock's current price.
View analysts price targets for PBLA or view top-rated stocks among Wall Street analysts.
How have PBLA shares performed in 2024?: Panbela Therapeutics' stock was trading at $18.30 on January 1st, 2024. Since then, PBLA stock has decreased by 97.7% and is now trading at $0.42.
View the best growth stocks for 2024 here.
When is Panbela Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBLA earnings forecast.

How were Panbela Therapeutics' earnings last quarter?: Panbela Therapeutics, Inc. (NASDAQ:PBLA) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($159.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($94.20) by $64.80. During the same quarter last year, the business earned ($36,276.20) earnings per share.
When did Panbela Therapeutics' stock split?: Panbela Therapeutics's stock reverse split on Thursday, January 18th 2024. The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
How do I buy shares of Panbela Therapeutics?: Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PBLA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Panbela Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Panbela Therapeutics Stock (NASDAQ:PBLA)

PBLA Stock Price History

PBLA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

PBLA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™